5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Laurus Labs Ltd.

•
lauruslabs.comBSE: 540222NSE: LAURUSLABS
Market Cap₹ 1,06,460 Cr.
Current Price
High / Low₹ 1,982 / 823
Stock P/E122.0
Book Value₹ 102
Price to Book10.24
Dividend Yield0.10 %
ROCE16.1 %
ROE15.2 %
Face Value₹ 2

Add ratio to table

ABOUT

KEY POINTS

Revenue Breakup Mar 2014 • Pharmaceuticals: 99.0% • Infosystems: 1.0%

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Latest quarter profit grew 83.6% YoY, showing strong momentum
  • Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.92x)
  • Institutional investors have been accumulating - FII+DII up 4.1pp
  • Company comfortably covers its interest (8.0x coverage)
  • Company has a consistent dividend-paying track record
  • Company maintains a comfortable, low leverage position

CONS

  • Company has a low return on capital employed of 11.4%
  • Company has a low return on equity of 9.8% over last 3 years
  • Company has delivered a poor profit growth of -5.0% over past five years
  • Stock is trading at 10.2x its book value
  • Company has delivered a poor sales growth of 5.0% over past five years

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTYM150MOMNTM50NIFTY ALPHA 50NIFTY PHARMANIFTY500MOMENTM50NIFTYLARGEMIDCAP250
S.No.Name
1.SUNPHARMA1842.0036.54441957.500.872901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9326.0084.64247576.000.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4975.0086.76189233.010.76566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1119.5024.74111670.550.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1365.0032.72110272.680.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1970.3597.37106460.420.10362.07123.942026.3129.1018.2031.50
7.DRREDDY1161.0030.0796906.380.69435.60-69.108099.80-5.2113.7510.63
8.AUROPHARMA1675.4525.9796401.690.241032.0325.229150.3517.4412.7620.54
9.LUPIN2096.0017.3495842.920.861416.9816.018276.8934.2828.8629.59
10.MANKIND2277.0046.0494050.370.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2416.9037.9468210.880.10482.83927.884018.4831.3520.3520.03
12.BIOCON390.95128.6363712.890.13136.8053.364336.0010.893.2619.54
Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
1,1081,1581,1321,4151,1171,1851,2651,6501,4331,5671,5091,5801,757
9809789621,1439561,0031,0591,2551,1051,1771,1641,2051,389
Operating Profit128181170271161182206395327390346375368
OPM %11.55%15.59%15.05%19.17%14.45%15.35%16.30%23.93%22.85%24.87%22.91%23.75%20.95%
7611249127722228141320
Interest33383842414548494434313435
Depreciation84858789919189889496949596
Profit before Tax176357164395877330211289234259388
Tax %24.23%26.17%24.80%26.16%25.82%26.94%25.35%23.71%25.30%25.33%25.32%26.06%25.30%
Net Profit134743121294257252158216175192290
0.240.870.792.250.530.791.064.682.933.993.253.555.37

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
1,8922,0272,2362,7974,7694,7075,7734,8125,2176,0896,413
1,4781,6181,8852,2273,2593,4224,2924,0634,2734,6514,934
Operating Profit4144093515701,5101,2851,4827509441,4381,479
OPM %21.87%20.17%15.72%20.38%31.66%27.30%25.67%15.58%18.10%23.62%23.06%
3229166272216471007776
Interest977586886696146151182143134
Depreciation104121161184197235301345359379381
Profit before Tax2452411213041,2759751,0513015049941,171
Tax %18.39%28.13%21.63%12.29%24.99%23.10%27.68%25.80%24.50%25.51%25.48%
Net Profit20017395267956750760224380740872
EPS21.8516.288.925.0117.7713.9114.094.157.0513.72—
Dividend Payout %8.00%9.19%16.81%10.01%11.22%14.33%14.17%19.27%17.01%14.58%—

COMPOUNDED SALES GROWTH

10 Years:
13%
5 Years:
5%
3 Years:
2%

COMPOUNDED PROFIT GROWTH

10 Years:
18%
5 Years:
-5%
3 Years:
-1%

STOCK PRICE CAGR

10 Years:
—
5 Years:
25%
3 Years:
72%
1 Year:
120%

RETURN ON EQUITY

10 Years:
17%
5 Years:
15%
3 Years:
10%
Last Year:
15%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Corporate actions

2026

May 8

₹ 0.60

Rs.1.2000 per share(60%)Interim Dividend

2025

Oct 31

₹ 0.40

Rs.0.8000 per share(40%)Interim Dividend

2025

May 9

₹ 0.40

Rs.0.8000 per share(40%)Interim Dividend

2024

Nov 6

₹ 0.20

Rs.0.4000 per share(20%)Interim Dividend

2024

May 8

₹ 0.20

Rs.0.4000 per share(20%)Interim Dividend

2023

Nov 2

₹ 0.20

Rs.0.4000 per share(20%)Interim Dividend

2023

May 10

₹ 0.60

Rs.1.2000 per share(60%)Interim Dividend

2022

Nov 3

₹ 0.40

Rs.0.8000 per share(40%)Interim Dividend

2022

May 10

₹ 0.60

Rs.1.2000 per share (60%) Second Interim Dividend

2021

Nov 17

₹ 0.40

Rs.0.8000 per share(40%)Interim Dividend

2021

May 11

₹ 0.40

Rs.0.8000 per share (40%) Third Interim Dividend

2021

Feb 8

₹ 0.20

Re.0.4000 per share (20%) Second Interim Dividend

2020

Nov 10

₹ 0.40

Rs.0.8000 per share(40%)Interim Dividend

2018

Jun 28

₹ 0.15

Rs.1.5000 per share(15%)Dividend

2017

Jul 6

₹ 0.15

Rs.1.5000 per share(15%)Dividend

2020

Apr 30

₹ 0.10

Rs.1.0000 per share(10%)Final Dividend

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital106106106107107107108108108108
1,2441,4011,4791,7042,6003,2723,9374,0784,4305,119
8711,0121,0691,1061,4811,7161,7551,8802,3832,308
Trade Payables2993074776041,1598496669979291,197
901331371496231,1301,2291,4141,6851,990
Total Liabilities2,6092,9593,2693,6705,9707,0747,6968,4779,53410,722
1,1931,4481,5991,6941,8182,1862,8843,0362,8883,041
Capital Work in Progress14316310767324755357156336569
51525858319362384635740891
5015766668931,5341,6891,5691,6971,7392,136
00000001,6402,0352,023
Cash & Bank211139412435138
7187208399561,9362,0422,4991,2691,7452,024
Total Assets2,6092,9593,2693,6705,9707,0747,6968,4779,53410,722

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
3714303193849219891,1506595401,385
Cash from Investing-282-417-257-217-900-837-735-757-592-847
Cash from Financing-4749-37-12724315-18513959-551
-80-00382-39418-13

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
27.1827.1827.6227.6227.5927.5927.4927.4927.47
25.6726.0825.5625.5125.7026.1726.5225.8228.00
13.5613.0512.7411.7811.9411.7212.4213.9613.73
Government0.000.000.000.000.000.000.000.000.00
33.5933.6934.0835.0934.7834.5133.5632.7130.79

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-10
Analysts/Institutional Investor Meet/Con. Call Updates

2026-09-10 - Laurus Labs Limited has informed the Exchange about Schedule of meet

2026-08-31
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-31 - Laurus Labs Limited has informed the Exchange about Schedule of meet

2026-08-12
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-12 - Laurus Labs Limited has informed the Exchange about Schedule of meet

2026-08-10
General Updates

2026-08-10 - Laurus Labs Limited has informed the Exchange about Intimation of ESG Score given by NSE Sustainability Ratings and Analytics Limited

2026-07-30
Analysts/Institutional Investor Meet/Con. Call Updates

2026-07-30 - Laurus Labs Limited has informed the Exchange about Transcript

2026-07-27
General Updates

2026-07-27 - Laurus Labs Limited has informed the Exchange about Allotment of ESOP

2026-07-25
General Updates

2026-07-25 - Laurus Labs Limited has informed the Exchange about Update On Composite Scheme of Arrangement

2026-07-25
Copy of Newspaper Publication

2026-07-25 - Laurus Labs Limited has informed the Exchange about Copy of Newspaper Publication

2026-07-24
Analysts/Institutional Investor Meet/Con. Call Updates

2026-07-24 - Laurus Labs Limited has informed the Exchange about Link of Recording

News

Recent coverage and analyst commentary for LAURUSLABS

Loading news…

🤖

AI Stock Analyst

Laurus Labs Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login